Cue Biopharma (CUE.US): The 2024 Q1 financial report achieved revenue of US$1,717,000, with a previous value of US$187,000 and an expected value of US$1.21 million; earnings per share were -0.25 dollars, the previous value was -0.29 dollars, and the expected value was -0.28 dollars.
Cue Biopharma(CUE.US)：2024年Q1财报实现营收171.7万美元，前值为18.7万美元，预期值为121万美元；每股收益为-0.25美元，前值为-0.29美元，预期值为-0.28美元。
Cue Biopharma (CUE.US): The 2024 Q1 financial report achieved revenue of US$1,717,000, with a previous value of US$187,000 and an expected value of US$1.21 million; earnings per share were -0.25 dollars, the previous value was -0.29 dollars, and the expec
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.